Business
Aeterna Zentaris Reports Third Quarter 2013 Financial and Operating Results
All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY , Nov. 5, 2013 ...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\nAll amounts are in U.S. dollars (unless otherwise noted)\n\n\nQUEBEC CITY, Nov. 5, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\"), a specialty biopharmaceutical company\n engaged in developing novel treatments in oncology and endocrinology,\n today reported financial and operating results as at and for the three\n months ended September 30, 2013.\n\n\nKey Highlights\n\n\nZoptarelin Doxorubicin (AEZS-108)\n\n\n\nInitiation of patient dosing in the Phase 3 \"ZoptEC\" (Zoptarelin doxorubicin in Endometrial Cancer) trial in women with endometrial cancer resistant to\n platinum/taxane-based chemotherapy.\n\n\n\nMacimorelin Acetate (AEZS-130)\n\n\n\nSubsequent to quarter-end, submission of a New Drug Application (\"NDA\")\n to the United States Food and Drug Administration (\"FDA\") for\n macimorelin acetate for the evaluation of Adult Growth Hormone\n Deficiency (\"AGHD\").\n\n\n\nCetrotide® \n\n\n\nSubsequent to quarter-end, successful completion of the transfer of\n Cetrotide® manufacturing rights in all territories to Merck Serono, in exchange\n for an upfront payment of €2.5 million (approximately $3.3 million).\n\n\n\n\"At-the-Market\" Issuance Program\n\n\n\nBetween May 21, 2013 and November 5, 2013, the Company sold a total of\n approximately 1.5 million common shares under its At-the-Market (\"ATM\")\n sales program at an average price of $1.80 per share, for aggregate\n gross proceeds of approximately $2.7 million. This includes\n approximately 0.8 million common shares at an average price of $1.50\n per share, for aggregate gross proceeds of approximately $1.2 million,\n between July 1 and November 5, 2013. This ATM allows the Company to\n sell up to a maximum of 2.5 million common shares through ATM issuances\n on the NASDAQ Capital Market® for aggregate gross proceeds not to exceed $4.6 million.\n\n\n\nRegistered Direct Offering\n\n\n\nCompletion of a registered direct offering of 5.2 million units at a\n purchase price of $1.50 per unit, generating net proceeds of\n approximately $7 million.\n\n\n\nAppointment to Management Team\n\n\n\nSubsequent to quarter-end, appointment of Jude Dinges as Senior Vice\n President, Chief Commercial Officer. \n\n\n\nCash and cash equivalents totalled $24.8 million as at September 30, 2013, compared t...